Trial Profile
A clinical study of Apatinib and radiofrequency ablation treatment in Patients with Lung Cancer
Status:
Recruiting
Phase of Trial:
Phase IV
Latest Information Update: 04 Apr 2017
Price :
$35
*
At a glance
- Drugs Rivoceranib (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 04 Apr 2017 New trial record